| Ticker: | RVPH |
| Current Price: | $0.35 |
| % Daily Change: | -9.13% |
| Volume (1,000s): | 7.02 |
| Average Volume (1,000s): | 384.50 |
| Market Cap (M): | $4.63 |
| 1/2/2024 Price: | $5.31 |
| Change Since Inception: | -93.41% |
Reviva Pharmaceuticals Holdings, Inc.
19925 Stevens Creek Boulevard
Suite 100
Cupertino, CA 95014
United States
Reviva Pharmaceuticals
We are a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases.
Our pipeline currently has two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house using our chemical genomics driven technology platform.
We have been granted composition of matter patents for both RP5063 and R1208 in the United States (U.S.), Europe, and several other countries.